<DOC>
	<DOCNO>NCT02732730</DOCNO>
	<brief_summary>To assess acceptance rate , adherence , acceptability , continuation oral pre-exposure prophylaxis ( PrEP ) among young southern African woman .</brief_summary>
	<brief_title>Uptake Adherence Daily Oral PrEP Primary Prevention Strategy Young African Women : A Vanguard Study</brief_title>
	<detailed_description>A Phase IV randomize multi-site prospective study ass PrEP acceptance adherence among HIV-uninfected young woman . All woman accept open-label daily oral PrEP randomize 1:1 receive enhance adherence counselling base feedback observed drug level standard adherence support . A subset ~25 woman per site ( maximum 75 ) , participate qualitative assessment facilitator barrier PrEP acceptance , adherence continuation .</detailed_description>
	<mesh_term>Emtricitabine , Tenofovir Disoproxil Fumarate Drug Combination</mesh_term>
	<criteria>Young woman meet follow criterion eligible inclusion study : Female birth Age 1625 year Per participant report , sexually active , define vaginal anal intercourse least month prior screen Literate one study languages Willing able provide inform consent assent ( parental consent require per local regulation ) If parental consent require per local regulation , parent/legal guardian willing able consent study procedure include HIV test Able willing provide adequate locator information , define site Standard Operating Procedures ( SOPs ) Have score 5 great Vaginal Oral Intervention Control Epidemic ( VOICE ) risk score tool Interest PrEP ( ascertain select question HIV Prevention Readiness Measure ( HPRM ) Prep Belief Measure ( PBM ) define Study Specific Procedures [ SSP ] Manual ) Regular access mobile phone SMS capacity Agrees participate research study involve drug medical device next 12 month Hepatitis B virus ( HBV ) seronegative accepts HBV vaccination . Young woman meet follow criterion exclude study : Planning relocate next 12 month Has job obligation would require long absence area ( &gt; 4 week time ) 12 month Any health condition may interfere participation , include debilitate lifethreatening condition Currently pregnant plan become pregnant next 12 month Any reactive positive HIV test Screening Enrollment , even subsequent test indicate person HIVuninfected Renal dysfunction ( Creatinine Clearance &lt; 60 ml/min , Schwartz Equation ) Any report PrEP use within last 12 month Concomitant participation clinical trial use investigational agent , include placebocontrolled clinical trial use agent Prior participation active arm , current participation arm , HIV vaccine trial Signs symptom acute HIV infection ( describe SSP Manual ) Current active serious infection could interfere study participation , include active tuberculosis infection , osteomyelitis , infection require parenteral antibiotic therapy ( STIs require intramuscular injection antibiotic ) ; active clinically significant medical problem include poorlycontrolled cardiac disease ( e.g. , symptoms ischemia , congestive heart failure ) , previously diagnose malignancy expect require treatment . Current use ARV drug postexposure prophylaxis ( PEP ) completion PEP regimen within 4 week prior Screening History pathological bone fracture relate trauma Known allergy/sensitivity study drug component Receiving ongoing therapy following : investigational ARV agent , interferon interleukin therapy , agent substantial nephrotoxic potential , agent may inhibit compete elimination via active renal tubular secretion ( e.g. , probenecid ) , and/or investigational agent Any condition , base opinion site Investigator Record ( IoR ) designee , would preclude provision inform consent , make participation project unsafe , complicate interpretation outcome data , otherwise interfere achieve project objective .</criteria>
	<gender>Female</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>25 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>ART ( Antir-retroviral therapy )</keyword>
	<keyword>PrEP ( Pre-Exposure Prophylaxis )</keyword>
	<keyword>DAIDS ( Division AIDS )</keyword>
	<keyword>HPTN ( HIV Prevention Trials Network )</keyword>
</DOC>